BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Colorcon
Covington
UBS
Express Scripts
Cipla
Accenture
Argus Health
Mallinckrodt
Cantor Fitzgerald

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,361,758

« Back to Dashboard

Which drugs does patent 6,361,758 protect, and when does it expire?

Patent 6,361,758 protects ZEMPLAR and is included in one NDA.

Protection for ZEMPLAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
Summary for Patent: 6,361,758
Title: Cosolvent formulations
Abstract:Stable pharmaceutical formulations of a therapeutic agent, a low molecular weight alcohol and a glycol derivative are disclosed. Preferred formulations include 19-nor-1.alpha.,3.beta.,25-trihydroxy-9,10-secoergosta-5,7(E),22(E)-triene .
Inventor(s): Li; Lukchiu (Vernon Hills, IL), Pec; Edward Anthony (Gurnee, IL), Robinson; Daniel H. (Lake Bluff, IL), Stephens; Dennis A. (Mt. Prospect, IL), Jantzi; Kathee (Madison, WI), May; Thomas Barton (Grayslake, IL), Oberdier; John Paul (Gurnee, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:09/689,507
Patent Claim Types:
see list of patent claims
Composition; Formulation;

Drugs Protected by US Patent 6,361,758

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-002 Feb 1, 2000 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-001 Apr 17, 1998 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-003 Feb 1, 2000 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Healthtrust
UBS
Cantor Fitzgerald
Novartis
Cipla
Deloitte
Accenture
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot